Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Subject: Undertaking Under Regulation 57(2) Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015

 Dear Sirs, We wish to inform you that in respect of Non-Convertible Debentures of the Company allotted on January 27, 2017, the Company has provided all the documents and intimations required to be submitted to the Debenture Trustees i.e. Vistra ITCL (India) Limited during the Financial Year 2017-18 in terms of the Debenture Trust Deed dated March 22, 2017 and the SEBI (Issue and Listing of Debt Securities) Regulations, 2008. This is for your information and records.
09-04-2018
Bigul

Board Meeting-Closure of Trading Window

 Sub: Intimation regarding closure of Trading Window Pursuant to the Company's Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the securities of the Company is closed for 'Designated Persons' from Friday, March 23, 2018 and the same shall remain closed till 48 hours after announcement of the financial results for the quarter ending March 31, 2018 to the Stock Exchanges....
23-03-2018
Bigul

Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jubilant Stock Holding Pvt Ltd
19-03-2018
Bigul

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Sub.: Intimation of participation in 10th Goldman Sachs India Pharma and Healthcare Tour on March 9, 2018 Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the management of the Company is participating in the 10th Goldman Sachs India Pharma and Healthcare Tour on March 9, 2018 in the National Capital...
08-03-2018
Bigul

Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jubilant Stock Holding Pvt Ltd
08-03-2018
Bigul

Announcement under Regulation 30 (LODR)-Updates

 We refer to our intimation dated March 4, 2018 to the stock exchanges where we had informed that the Commissioner of State Excise, Maharashtra has passed an order dated March 3, 2018 ('Order') cancelling our DS-1 License and Form-I License relating to the distillery operations at one of our factories located at Nira, Maharashtra and for taking necessary criminal action....
07-03-2018
Bigul

Announcement under Regulation 30 (LODR)-Updates

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Commissioner of State Excise, Maharashtra has passed an order dated March 3, 2018 cancelling our DS-1 License and Form-I License relating to the Distillery operations of one of our factories located at Nira, Maharashtra and to take necessary criminal action....
04-03-2018
Bigul

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jubilant Advisors LLP, MAV Management Advisors LLP & Jubilant Consumer Pvt Ltd
23-02-2018
Bigul

Jubilant Life Sciences falls 11% after block deals

 The stock slipped 11% to Rs 883 on the NSE in intra-day trade on Friday after a more than seven per cent of the total equity of pharmaceutical company changed hands on the NSE and BSE till noon deal.
23-02-2018
Bigul

Jubilant Pharma gets USFDA nod for generic version of anti-viral drug

 Drug firm Jubilant Life Sciences today said its subsidiary has received final approval from the US health regulator for Amantadine Hydrochloride tablets, an anti-viral and anti-Parkinsons drug. T
09-02-2018
Next Page
Close

Let's Open Free Demat Account